Other · developed by Kiniksa Pharmaceuticals International
KPL-387 is a drug administered by subcutaneous injection. It is studied in pericarditis, including acute and recurrent pericarditis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07010159 | Phase 2/3 | Pericarditis | Recruiting | KNSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
PericarditisPericarditis AcuteRecurrent Pericarditis
Updated Oct 18, 2026. Something wrong or missing? Report it on the KNSA page.
See KNSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KNSA catalysts and pipeline →